Literature DB >> 8268722

Duchenne muscular dystrophy--Meryon's disease.

A E Emery1.   

Abstract

In a communication to the Royal Medical and Chirurgical Society of London in December 1851, which was published in the Transactions of the Society the following year, Edward Meryon, an English physician, described, in considerable detail, eight boys in three families with a disease later referred to as Duchenne muscular dystrophy. He was particularly impressed by the predilection for males and its familial nature, and that the progressive muscle wasting and weakness was essentially due to a disease of muscle and not the nervous system. His detailed histological studies revealed no abnormality of the spinal cord or nerves but in muscle tissue he noted extensive "granular degeneration" and in particular that the sarcolemma was broken down and destroyed. He appears to have been the first physician to make a detailed clinical, genetic, and pathological study of the disorder several years before Duchenne.

Entities:  

Mesh:

Year:  1993        PMID: 8268722     DOI: 10.1016/0960-8966(93)90018-f

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  20 in total

1.  2015 William Allan Award.

Authors:  Kay E Davies
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

2.  Blocking the myostatin signal with a dominant negative receptor improves the success of human myoblast transplantation in dystrophic mice.

Authors:  Raouia Fakhfakh; Annick Michaud; Jacques P Tremblay
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

3.  Upper extremity 3-dimensional reachable workspace analysis in dystrophinopathy using Kinect.

Authors:  Jay J Han; Gregorij Kurillo; Richard T Abresch; Evan De Bie; Alina Nicorici; Ruzena Bajcsy
Journal:  Muscle Nerve       Date:  2015-06-03       Impact factor: 3.217

Review 4.  Synergizing Engineering and Biology to Treat and Model Skeletal Muscle Injury and Disease.

Authors:  Nenad Bursac; Mark Juhas; Thomas A Rando
Journal:  Annu Rev Biomed Eng       Date:  2015       Impact factor: 9.590

5.  Myotendinous junction defects and reduced force transmission in mice that lack alpha7 integrin and utrophin.

Authors:  Jennifer V Welser; Jachinta E Rooney; Nicolette C Cohen; Praveen B Gurpur; Cherie A Singer; Rebecca A Evans; Bryan A Haines; Dean J Burkin
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

6.  Cerebellar-dependent associative learning is preserved in Duchenne muscular dystrophy: a study using delay eyeblink conditioning.

Authors:  Ulrike Schara; Melanie Busse; Dagmar Timmann; Marcus Gerwig
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

7.  Second-generation compound for the modulation of utrophin in the therapy of DMD.

Authors:  Simon Guiraud; Sarah E Squire; Benjamin Edwards; Huijia Chen; David T Burns; Nandini Shah; Arran Babbs; Stephen G Davies; Graham M Wynne; Angela J Russell; David Elsey; Francis X Wilson; Jon M Tinsley; Kay E Davies
Journal:  Hum Mol Genet       Date:  2015-05-01       Impact factor: 6.150

Review 8.  Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.

Authors:  Simon Guiraud; Huijia Chen; David T Burns; Kay E Davies
Journal:  Exp Physiol       Date:  2015-08-04       Impact factor: 2.969

Review 9.  Mechanical regulation of gene expression in cardiac myocytes and fibroblasts.

Authors:  Jeffrey J Saucerman; Philip M Tan; Kyle S Buchholz; Andrew D McCulloch; Jeffrey H Omens
Journal:  Nat Rev Cardiol       Date:  2019-06       Impact factor: 32.419

10.  Skeletal muscle-specific ablation of gamma(cyto)-actin does not exacerbate the mdx phenotype.

Authors:  Kurt W Prins; Dawn A Lowe; James M Ervasti
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.